Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease - PubMed (original) (raw)

. 2024 Sep;39(9):1939-1949.

doi: 10.1111/jgh.16592. Epub 2024 May 9.

Tzu-I Chen 1, Szu-Ching Yin 1, Chia-Wei Huang 1 2, Jee-Fu Huang 3 4 5, Sheng-Nan Lu 6, Ming-Lun Yeh 3 4 5, Chung-Feng Huang 3 4 5, Chia-Yen Dai 3 4 5, Yu-Wei Chen 1 7 8 9, Wan-Long Chuang 3 4 5, Ming-Lung Yu 3 6 10 11 12, Mei-Hsuan Lee 1 2 12 13

Affiliations

Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease

Yi-Ting Chen et al. J Gastroenterol Hepatol. 2024 Sep.

Abstract

Background and aim: This study estimated the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) according to cardiometabolic risk factors. The long-term impacts of MASLD on all-cause and cardiometabolic-specific mortality were evaluated.

Methods: We enrolled 343 816 adults aged ≥30 years who participated in a health screening program from 1997 through 2013. MASLD was identified on the basis of abdominal ultrasonography and metabolic profiles. The participants were further categorized by liver enzyme elevation. Baseline cardiometabolic comorbidities were classified on the basis of self-reported medication use and clinical seromarkers. All-cause and cardiometabolic-specific deaths were determined through computerized data linkage with nationwide death certifications until December 31, 2020.

Results: The overall prevalence of MASLD was 36.4%. Among patients with MASLD, 35.9% had abnormal liver enzyme levels. Compared with patients without MASLD, abnormal liver enzymes were positively associated with cardiometabolic comorbidities in patients with MASLD (Pfor trend < 0.001). After follow-up, patients with MASLD had a 9%-29% higher risk of all-cause, cardiovascular-related, or diabetes-related mortality. In the groups with MASLD and elevated and normal liver enzyme levels, the multivariate-adjusted hazard ratios for cardiovascular deaths were 1.14 (1.05-1.25) and 1.10 (1.03-1.17), respectively, and those for diabetes deaths were 1.42 (1.05-1.93) and 1.24 (0.98-1.57), respectively, compared with those in the non-MASLD group (Pfor trend < 0.001).

Discussion: Individuals with MASLD and elevated liver enzyme levels exhibited significantly higher risks of all-cause and cardiometabolic deaths and should be monitored and given consultation on cardiometabolic modifications.

Keywords: long‐term risk; nonalcoholic fatty liver disease; noncommunicable diseases.

© 2024 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

PubMed Disclaimer

References

    1. Bennett JE, Stevens GA, Mathers CD et al. NCD countdown 2030: worldwide trends in non‐communicable disease mortality and progress towards sustainable development goal target 3.4. Lancet 2018; 392: 1072–1088.
    1. Younossi Z, Tacke F, Arrese M et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69: 2672–2682.
    1. Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023; 79: 1542–1556.
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
    1. Huang YH, Chan C, Lee HW et al. Influence of nonalcoholic fatty liver disease with increased liver enzyme levels on the risk of cirrhosis and hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2022.

MeSH terms

Substances

Grants and funding

LinkOut - more resources